Anzeige
Mehr »
Mittwoch, 08.10.2025 - Börsentäglich über 12.000 News
Defence-Aktie mit Ritterschlag: Regierungs-Einladung zur größten Militärmesse
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41BED | ISIN: SE0024173637 | Ticker-Symbol: 7AL0
Stuttgart
08.10.25 | 11:30
0,418 Euro
+9,86 % +0,038
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALLIGATOR BIOSCIENCE AB Chart 1 Jahr
5-Tage-Chart
ALLIGATOR BIOSCIENCE AB 5-Tage-Chart

Aktuelle News zur ALLIGATOR BIOSCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09:02Alligator Bioscience: Alligator Announces Publication of OPTIMIZE-1 Biomarker Analysis in Cell Reports Medicine Supporting mitazalimab and mFOLFIRINOX in Metastatic Pancreatic Cancer118LUND, SE / ACCESS Newswire / October 8, 2025 / Alligator Bioscience (Nasdaq Stockholm: ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs...
► Artikel lesen
ALLIGATOR BIOSCIENCE Aktie jetzt für 0€ handeln
MoAlligator Bioscience Announces Acceptance of Two Abstracts at SITC 40th Anniversary Annual Meeting141LUND, SWEDEN / ACCESS Newswire / October 6, 2025 / Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced...
► Artikel lesen
22.09.Alligator Bioscience: Alligator Announces Final 30-Month OPTIMIZE-1 Results Highlighting the Potential of Mitazalimab in Metastatic Pancreatic Cancer197LUND, SE / ACCESS Newswire / September 22, 2025 / Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody...
► Artikel lesen
17.09.Alligator Bioscience AB Announces Final Outcome of Exercise of Warrants Series TO 13239LUND, SWEDEN / ACCESS Newswire / September 17, 2025 / Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS...
► Artikel lesen
16.09.Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 13244LUND, SE / ACCESS Newswire / September 16, 2025 / Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS...
► Artikel lesen
12.09.Alligator Bioscience: Alligator to Present New Preclinical Results on ATOR-4066 at CICON25271LUND, SE / ACCESS Newswire / September 12, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, announced...
► Artikel lesen
11.09.Last Day of Trading in Warrants Series TO 13 in Alligator Bioscience is 11 September 2025254LUND, SE / ACCESS Newswire / September 11, 2025 / Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA...
► Artikel lesen
10.09.Alligator Bioscience: Alligator Announces Publication in Cancer Immunology Research of Preclinical Data on ATOR-4066, a Tumor-Directed CD40×CEACAM5 Bispecific Antibody260LUND, SE / ACCESS Newswire / September 10, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today...
► Artikel lesen
09.09.Alligator Bioscience Has Renegotiated the Outstanding Loan From Fenja Capital and Received Subscription Intentions From Members of the Board of Directors and Management361NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH...
► Artikel lesen
08.09.Alligator Bioscience: Grant Awarded to Investigator-Initiated Phase 2/3 Trial with Mitazalimab in Biliary Tract Cancer280LUND, SE / ACCESS Newswire / September 8, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today...
► Artikel lesen
05.09.Alligator Bioscience to present at BioStock's "Investing in Life Science" event250LUND, SE / ACCESS Newswire / September 5, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today...
► Artikel lesen
02.09.Alligator Bioscience: Alligator Announces Evaluation and Option Agreement Covering RUBY Antibody Format267LUND, SWEDEN / ACCESS Newswire / September 2, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that Alligator has entered into an evaluation and option agreement with an infectious...
► Artikel lesen
27.08.Exercise Price Determined for the Exercise of Warrants Series TO 13 in Alligator Bioscience AB316NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA...
► Artikel lesen
20.08.Alligator Bioscience Provides Highlights from R&D Event 2025552LUND, SE / ACCESS Newswire / August 20, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, provides...
► Artikel lesen
14.08.Alligator Bioscience to Host Virtual R&D Day on 19 August 2025284LUND, SE / ACCESS Newswire / August 14, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announces...
► Artikel lesen
25.07.Alligator Bioscience Announces Upcoming Presentation of REACtiVe-2 Phase 1 Data at ESMO Congress 2025317LUND, SE / ACCESS Newswire / July 25, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announces...
► Artikel lesen
14.07.Alligator Bioscience Comments on Henlius Dosing First Patient in the US in Phase 3 Trial of HLX22 in Gastric Cancer247LUND, SWEDEN / ACCESS Newswire / July 14, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that it has dosed the first patient...
► Artikel lesen
10.07.Alligator Bioscience: Operativer Verlust in Q2 2025 belastet Aktienkurs3
10.07.Alligator Bioscience AB Reports Financial Results for Q2 2025 and Provides a Business Update645GMP manufacturing completed, paediatric waiver granted, positive outcome from FDA and EMA interactions; advancing mitazalimab toward Phase 3 readinessBiomarker data from OPTIMIZE-1 presented at ASCO...
► Artikel lesen
01.07.Alligator Bioscience: Alligator to Present 24-Month OPTIMIZE-1 Data at ESMO GI 2025398LUND, SWEDEN / ACCESS Newswire / July 1, 2025 / Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that...
► Artikel lesen
Weiter >>
84 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3